Ixazomib Rollover Study
Multiple Myeloma · Lymphoma · Amyloidosis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.9
2 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 32 (final count)
- Started
- Dec 16, 2016
- Main results expected
- Jul 3, 2024
- Fully finished
- Jul 3, 2024
- Results posted
- Mar 12, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants With Serious Adverse Events (SAEs)
Measured over: Up to 7 years
Number of Participants With ≥ Grade 3 AEs
Measured over: Up to 7 years
Number of Participants With ≥ Grade 2 Peripheral Neuropathy
Measured over: Up to 7 years
Number of Participants With New Primary Malignancies
Measured over: Up to 7 years
Number of Participants With Any AE Resulting in Dose Modification or Discontinuation of Any Study Drug
Measured over: Up to 7 years
Number of Participants With Any Other AE That in the Opinion of the Investigator is a Clinically Significant Event
Measured over: Up to 7 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.9, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02924272 · record last updated 2025-03-12 · checked 2026-11-09 15:47 UTC